CADL Stock Analysis: Buy, Sell, or Hold?
CADL - Candel Therapeutics, Inc. Common Stock
$13.75
0.47 (3.54%)
▲
5d:
+11.34%
30d:
+46.28%
90d:
+69.96%
WAIT
LOW Confidence
Analysis Updated: Aug 27, 2026 12:00 AM ET
Earnings: Aug 13, 2026
0d
Get Alerted When CADL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: CADL shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: CADL shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: CADL is currently trading at $13.75, which is considered extended relative to its 30-day fair value range of $9.74 to $12.50. From a valuation perspective, the stock is trading at a discount (Forward PE: -22.0) compared to its historical average (40.5). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CADL is in a strong uptrend. The price is approaching resistance at $14.00. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.5% recently.
Market Sentiment: CADL scores 5/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $21.00 (+52.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CADL is in a strong uptrend. The price is approaching resistance at $14.00. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.5% recently.
Market Sentiment: CADL scores 5/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $21.00 (+52.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$9.74 -
$12.50
Company Quality Score
36/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
33.3%
All Signals
- BEARISH: Price extended above range (+10.0% above its trading range)
- BEARISH: Weak technical setup (5/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.5%)
- BULLISH: Trading 52.7% below Wall St target ($21.00)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 36/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$9.74 -
$12.50
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$11.04
Resistance Level
$14.00
Current Trend
Strong Uptrend
Technical data as of
Aug 27, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-22.00
Wall Street Target
$21.00
(+52.7%)
PE vs Historical
-22.0 vs 40.5
CHEAP
Share & Embed Analysis
Last updated: August 27, 2026 9:18 PM ET
Data refreshes hourly during market hours. Next update: 10:18 PM
Data refreshes hourly during market hours. Next update: 10:18 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CADL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 57 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 49 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$88 | 35 SELL |
|
ARVN
Arvinas Inc |
BUY
21 analysts |
$14 | 50 HOLD |
